Related Experiment Video
Updated: Mar 14, 2026
07:29
Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
Published on: June 20, 2015
20.2K
Metformin: Antidiabetic actions from cells to tissues.
Clifford J Bailey1, Michael Gwilt2, Kerstin M G Brand3
1Health and Life Sciences, Aston University, Birmingham, UK.
Metabolism: Clinical and Experimental
|March 12, 2026
Summary
Metformin, a key type 2 diabetes drug, works through diverse cellular actions affecting nutrient metabolism and energy. Its concentration-dependent effects in different tissues offer potential for managing other disorders.
Area of Science:
- Pharmacology
- Cellular Biology
- Metabolic Disorders
Background:
- Metformin is a primary treatment for hyperglycemia in type 2 diabetes.
- It improves insulin sensitivity, glucose homeostasis, and aids weight management.
- Metformin's actions include reducing hepatic glucose production and increasing glucose uptake.
Purpose of the Study:
- To elucidate the diverse cellular mechanisms of metformin.
- To understand how metformin's actions vary by tissue and concentration.
- To explore potential therapeutic applications beyond diabetes.
Main Methods:
- Analysis of metformin's effects on mitochondrial respiration (complex 1 and 4).
- Investigation of AMP-activated protein kinase (AMPK) activation pathways.
- Examination of metformin's impact on metabolic enzymes and signaling intermediates.
Main Results:
- High metformin concentrations inhibit mitochondrial complex 1, activating AMPK.
- Lower concentrations affect mitochondrial complex 4, impacting glycerol metabolism.
- Low concentrations activate AMPK via a lysosomal pathway without altering oxidative metabolism.
Conclusions:
- Metformin's antidiabetic effects stem from concentration-dependent cellular actions on metabolism and energetics.
- Its broad cellular effects suggest potential in treating cardiovascular, inflammatory, and neurodegenerative diseases.
Related Concept Videos
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
796
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
796
01:16Hormones Regulating Blood Glucose
8.1K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
8.1K
01:06Oral Hypoglycemic Agents: Glinides
804
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
804
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
738
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
738
01:28Insulin: The Receptor and Signaling Pathways
5.5K
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
5.5K
01:23Dipeptidyl Peptidase 4 Inhibitors
860
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
860